WP1066

CAS No. 857064-38-1

WP1066( STAT Inhibitor III )

Catalog No. M16217 CAS No. 857064-38-1

WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 46 In Stock
5MG 42 In Stock
10MG 70 In Stock
25MG 126 In Stock
50MG 209 In Stock
100MG 293 In Stock
200MG Get Quote In Stock
500MG 714 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WP1066
  • Note
    Research use only, not for human use.
  • Brief Description
    WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells.
  • Description
    WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    STAT Inhibitor III
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK2| STAT3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    857064-38-1
  • Formula Weight
    356.22
  • Molecular Formula
    C17H14BrN3O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 71 mg/mL (199.31 mM)
  • SMILES
    O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
  • Chemical Name
    (S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Verstovsek S, et al. Clin Y Res, 2008, (3), 788-796.
molnova catalog
related products
  • AZ960

    A potent, selective JAK2 inhibitor with Ki of 0.45 nM, IC50 of <3 nM.

  • JAK2-IN-7

    JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.

  • Fosifidancitinib

    Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.